CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple...
Phase 1
Saint Louis, Missouri, United States and 5 other locations
and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...
Phase 2
Saint Louis, Missouri, United States and 25 other locations
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma...
Phase 1
Saint Louis, Missouri, United States and 13 other locations
The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant...
Phase 2
Saint Louis, Missouri, United States and 9 other locations
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...
Phase 2
Saint Louis, Missouri, United States and 31 other locations
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
Saint Louis, Missouri, United States and 59 other locations
This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bisp...
Phase 1, Phase 2
Saint Louis, Missouri, United States and 13 other locations
This study includes extended CD34+ profiling on the apheresis product of multiple myeloma patients undergoing standard-of-care quad...
Phase 1
Saint Louis, Missouri, United States
progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...
Phase 3
Saint Louis, Missouri, United States and 211 other locations
This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and efficacy of ISB 1442 in relapsed/refractory multiple...
Phase 1, Phase 2
Saint Louis, Missouri, United States and 14 other locations
Clinical trials
Research sites
Resources
Legal